TP53 is frequently altered by methylation, mutation, and/or deletion in acute lymphoblastic leukaemia

被引:63
作者
Agirre, X [1 ]
Novo, FJ [1 ]
Calasanz, MJ [1 ]
Larráyoz, MJ [1 ]
Lahortiga, I [1 ]
Valgañón, M [1 ]
García-Delgado, M [1 ]
Vizmanos, JL [1 ]
机构
[1] Univ Navarra, Dept Genet, Sch Sci, E-31080 Pamplona, Navarra, Spain
关键词
DGGE; promoter hypermethylation; FISH; ALL; TUMOR-SUPPRESSOR GENE; GRADIENT GEL-ELECTROPHORESIS; B-CELL LYMPHOMA; WILD-TYPE P53; DNA METHYLATION; HEMATOLOGICAL MALIGNANCIES; CPG METHYLATION; POINT MUTATIONS; IN-VIVO; PROMOTER;
D O I
10.1002/mc.10159
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Different mechanisms, such as chromosomal rearrangements, deletions, mutations, and methylation/demethylation of the promoter regions of genes, have been shown to be involved in acute lymphoblastic leukaemia (ALL). These genetic and epigenetic alterations lead to the activation of protooncogenes or to inactivation of tumour supressor genes promoting cell proliferation. One of the most frequently inactivated tumour supressor genes is TP53, which is altered in 50% of human tumours. In this study, we have analysed: (1) the complete coding region, all intron-exon junctions and noncoding regions of exons 1-11 of TP53 by lexon-DGGE;- (2) the methylation status of the 5' region of TP53 and (3) the deletion of one or both alleles of the gene by fluorescence in situ hybridisation (FISH) in 57 ALL patients. Using these techniques, we have found promoter methylation in 32% of the cases, missense mutations in 8.8%, and deletion of one allele in 7.5% of the samples, with TP53 being altered in 40% of the ALL samples studied in this series. (C) 2003 Wiley-Liss, Inc.
引用
收藏
页码:201 / 208
页数:8
相关论文
共 44 条
[1]   Methylation of CpG dinucleotides and/or CCWGG motifs at the promoter of TP53 correlates with decreased gene expression in a subset of acute lymphoblastic leukemia patients [J].
Agirre, X ;
Vizmanos, JL ;
Calasanz, MJ ;
García-Delgado, M ;
Larráyoz, MJ ;
Novo, FJ .
ONCOGENE, 2003, 22 (07) :1070-1072
[2]   Exon concatenation to increase the efficiency of mutation screening by DGGE [J].
Agirre, X ;
García-Delgado, M ;
Calasanz, MJ ;
Larráyoz, MJ ;
Novo, FJ ;
Vizmanos, JL .
BIOTECHNIQUES, 2002, 32 (05) :1064-+
[3]  
Berns EMJJ, 2000, CANCER RES, V60, P2155
[4]   THE 5' REGION OF THE P53 GENE - EVOLUTIONARY CONSERVATION AND EVIDENCE FOR A NEGATIVE REGULATORY ELEMENT [J].
BIENZTADMOR, B ;
ZAKUTHOURI, R ;
LIBRESCO, S ;
GIVOL, D ;
OREN, M .
EMBO JOURNAL, 1985, 4 (12) :3209-3213
[5]   P53 and angiogenesis [J].
Bouck, N .
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 1996, 1287 (01) :63-66
[6]  
Caron De Fromentel Claude, 1992, Genes Chromosomes and Cancer, V4, P1
[7]   REFINED SOLUTION STRUCTURE OF THE OLIGOMERIZATION DOMAIN OF THE TUMOR-SUPPRESSOR P53 [J].
CLORE, GM ;
ERNST, J ;
CLUBB, R ;
OMICHINSKI, JG ;
KENNEDY, WMP ;
SAKAGUCHI, K ;
APPELLA, E ;
GRONENBORN, AM .
NATURE STRUCTURAL BIOLOGY, 1995, 2 (04) :321-333
[8]   Dietary selenium and arsenic affect DNA methylation in vitro in Caco-2 cells and in vivo in rat liver and colon [J].
Davis, CD ;
Uthus, EO ;
Finley, JW .
JOURNAL OF NUTRITION, 2000, 130 (12) :2903-2909
[9]   5′ region and exon 7 mutations of the TP53 gene in two cases of B-cell prolymphocytic leukemia [J].
De Angeli, C ;
Cuneo, A ;
Aguiari, G ;
Roberti, MG ;
Piva, N ;
Moretti, S ;
Cavazzini, P ;
Castoldi, G ;
del Senno, L .
CANCER GENETICS AND CYTOGENETICS, 1998, 107 (02) :137-143
[10]   Analysis of-the P53, RB/D13S25, and P16 tumor suppressor genes in marginal zone B-cell lymphoma:: An interphase fluorescence in situ hybridization study [J].
Dierlamm, J ;
Stefanova, M ;
Wlodarska, I ;
Hinz, K ;
Maes, B ;
Michaux, L ;
Stul, M ;
Verhoef, G ;
Thomas, J ;
De Wolf-Peeters, C ;
Van den Berghe, H ;
Hossfeld, HK ;
Hagemeijer, A .
CANCER GENETICS AND CYTOGENETICS, 2000, 120 (01) :1-5